Some studies of tumor necrosis factor α (TNF-α)-targeting drugs found that dose reduction or discontinuation of biological agents can be achieved in a relevant proportion of RA patients without loss of disease control or radiological damage [7–9]. The gene discussed is TNF; the disease is rheumatoid arthritis.